This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bossard, C. Articles by Prats, H. Search for Related Content PubMed PubMed Citation Articles by Bossard, C. Articles by Prats, H.

Antiangiogenic Properties of Fibstatin, an Extracellular FGF-2–Binding Polypeptide

¹ Institut National de la Santé et de la Recherche Médicale (INSERM) U589, C.H.U. Rangueil, Toulouse, France; and ² INRA-CNRS UMR Saint Christol Lès Alès, France

By using the two-hybrid system with basic fibroblast growth factor (FGF-2) as bait, we isolated and characterized fibstatin, an endogenous M_r 29,000 human basement membrane-derived inhibitor of angiogenesis and tumor growth. Fibstatin, a fragment containing the type III domains 12–14 of fibronectin, was produced as a recombinant protein and was shown to inhibit the proliferation, migration, and differentiation of endothelial cells in vitro. Antiangiogenic activity of fibstatin was confirmed in a Matrigel angiogenesis assay in vivo, and electrotransfer of the fibstatin gene into muscle tissue resulted in reduced B16F10 tumor growth. Taken together, these results suggest that fibstatin could act as a powerful molecule for antiangiogenic therapy.

This article has been cited by other articles:

				O. P. Milling Smith, S. Battersby, K. J. Sales, H. O. D. Critchley, and H. N. Jabbour Prostacyclin Receptor Up-Regulates the Expression of Angiogenic Genes in Human Endometrium via Cross Talk with Epidermal Growth Factor Receptor and the Extracellular Signaling Receptor Kinase 1/2 Pathway Endocrinology, April 1, 2006; 147(4): 1697 - 1705. [Abstract] [Full Text] [PDF]